2-(3-fluorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine | 1422198-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-fluorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine
• 英文别名: 2-(3-fluorophenyl)-5-(piperidin-1-yl)oxazolo[5,4-b]pyridine；2-(3-Fluorophenyl)-5-piperidin-1-yl-[1,3]oxazolo[5,4-b]pyridine；2-(3-fluorophenyl)-5-piperidin-1-yl-[1,3]oxazolo[5,4-b]pyridine
• CAS: 1422198-99-9
• 化学式: C₁₇H₁₆FN₃O
• 分子量: 297.332
• InChiKey: MKPHXBPQXKVPAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  间氟苯甲酰氯 在 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 34.0h， 生成 2-(3-fluorophenyl)-5-(piperidine-1-yl)oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson’s disease

  摘要：

  In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R-1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound in with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.066

文献信息

• PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE AND METHOD OF SCREENING THE SAME
  申请人：LEE Changjoon Justin

  公开号：US20130046093A1

  公开（公告）日：2013-02-21

  A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

  一种用于预防或治疗退行性脑疾病的药物组合物，以及一种筛选预防或治疗退行性脑疾病材料的方法。该方法可以有效地筛选预防或治疗退行性脑疾病的预防性或治疗性候选材料。使用该药物组合物，包括筛选用于预防或治疗退行性脑疾病的材料，可以有效预防或治疗各种退行性脑疾病。
• Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
  申请人：Korea Institute of Science and Technology

  公开号：EP2560008A2

  公开（公告）日：2013-02-20

  A pharmaceutical composition for preventing or treating a degenerative brain disease, and a method of screening a material for preventing or treating a degenerative brain disease. The method may effectively screen a prophylactic or therapeutic candidate material for preventing or treating a degenerative brain disease. A variety of degenerative brain diseases may be effectively prevented or treated using the pharmaceutical composition including a screened material for preventing or treating a degenerative brain disease.

  一种用于预防或治疗退行性脑病的药物组合物，以及一种用于预防或治疗退行性脑病的材料筛选方法。 该方法可有效筛选出预防或治疗变性脑病的候选材料。 使用包括经筛选的用于预防或治疗退行性脑病的材料的药物组合物，可有效预防或治疗各种退行性脑病。
• US9469653B2
  申请人：——

  公开号：US9469653B2

  公开（公告）日：2016-10-18
• Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson’s disease
  作者：Hye Ri Park、Jiyoon Kim、Taekeun Kim、Seonmi Jo、Miyoung Yeom、Bongjin Moon、Il Han Choo、Jaeick Lee、Eun Jeong Lim、Ki Duk Park、Sun-Joon Min、Ghilsoo Nam、Gyochang Keum、C. Justin Lee、Hyunah Choo

  DOI：10.1016/j.bmc.2013.05.066

  日期：2013.9

  In Parkinson's disease, the motor impairments are mainly caused by the death of dopaminergic neurons. Among the enzymes which are involved in the biosynthesis and catabolism of dopamine, monoamine oxidase B (MAO-B) has been a therapeutic target of Parkinson's disease. However, due to the undesirable adverse effects, development of alternative MAO-B inhibitors with greater optimal therapeutic potential towards Parkinson's disease is urgently required. In this study, we designed and synthesized the oxazolopyridine and thiazolopyridine derivatives, and biologically evaluated their inhibitory activities against MAO-B. Structure-activity relationship study revealed that the piperidino group was the best choice for the R-1 amino substituent to the oxazolopyridine core structure and the activities of the oxazolopyridines with various phenyl rings were between 267.1 and 889.5 nM in IC50 values. Interestingly, by replacement of the core structure from oxazolopyrine to thiazolopyridine, the activities were significantly improved and the compound in with the thiazolopyridine core structure showed the most potent activity with the IC50 value of 26.5 nM. Molecular docking study showed that van der Waals interaction in the human MAO-B active site could explain the enhanced inhibitory activities of thiazolopyridine derivatives. (C) 2013 Elsevier Ltd. All rights reserved.